StockData
ImmuCell Corp logo

ImmuCell Corp (ICCC) stock

ICCCNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 13/303% above fair value
$11.25−0.08 (-0.71%)

Close on Nov 18, 2026Market cap $102.18MP/E 140.6Yield –

ImmuCell operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

ImmuCell's operating income for the twelve months ending Jun 30, 2026 was $3.87M, up 123.0% year over year. For fiscal 2025 it was $1.65M. Over ten years it grew -2.5% a year on average. The highest annual figure on record is $2.12M in fiscal 2015.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025$1.65M–
FY2024Dec 31, 2024-$1.64M–
FY2023Dec 31, 2023-$5.75M–
FY2022Dec 31, 2022-$2.30M-993.2%
FY2021Dec 31, 2021$257.39K–
FY2020Dec 31, 2020-$1.38M–
FY2019Dec 31, 2019-$953.91K–
FY2018Dec 31, 2018-$1.45M–
FY2017Dec 31, 2017-$242.85K-127.3%
FY2016Dec 31, 2016$890.20K-58.1%
FY2015Dec 31, 2015$2.12M–
FY2014Dec 31, 2014-$206.40K–
FY2013Dec 31, 2013-$19.55K-108.0%
FY2012Dec 31, 2012$245.00K–
FY2011Dec 31, 2011-$632.73K–
FY2010Dec 31, 2010-$690.28K–
FY2009Dec 31, 2009-$529.91K–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$1.93M+239.7%
Q1 FY2026Mar 31, 2026$1.97M+76.2%
Q4 FY2025Dec 31, 2025-$57.96K-109.3%
Q3 FY2025Sep 30, 2025$20.08K–
Q2 FY2025Jun 30, 2025$569.56K–
Q1 FY2025Mar 31, 2025$1.12M–
Q4 FY2024Dec 31, 2024$621.40K–
Q3 FY2024Sep 30, 2024-$574.89K–
Q2 FY2024Jun 30, 2024-$1.39M–
Q1 FY2024Mar 31, 2024-$300.05K–
Q4 FY2023Dec 31, 2023$0–
Q3 FY2023Sep 30, 2023-$1.18M–
Q2 FY2023Jun 30, 2023-$1.30M–
Q1 FY2023Mar 31, 2023-$2.26M-495.4%
Q4 FY2022Dec 31, 2022-$1.63M-1223.5%
Q3 FY2022Sep 30, 2022-$616.79K-327.5%
Q2 FY2022Jun 30, 2022-$619.01K-387.2%
Q1 FY2022Mar 31, 2022$570.61K–
Q4 FY2021Dec 31, 2021$145.41K–
Q3 FY2021Sep 30, 2021$271.09K–
Q2 FY2021Jun 30, 2021$215.51K–
Q1 FY2021Mar 31, 2021-$374.63K-290.3%
Q4 FY2020Dec 31, 2020-$634.36K–
Q3 FY2020Sep 30, 2020-$251.60K–
Q2 FY2020Jun 30, 2020-$691.27K–
Q1 FY2020Mar 31, 2020$196.88K-25.8%
Q4 FY2019Dec 31, 2019-$242.47K–
Q3 FY2019Sep 30, 2019-$429.82K–
Q2 FY2019Jun 30, 2019-$546.93K–
Q1 FY2019Mar 31, 2019$265.30K–
Q4 FY2018Dec 31, 2018-$925.87K–
Q3 FY2018Sep 30, 2018-$149.14K–
Q2 FY2018Jun 30, 2018-$193.41K–
Q1 FY2018Mar 31, 2018-$178.16K-119.4%
Q4 FY2017Dec 31, 2017-$413.34K-446.4%
Q3 FY2017Sep 30, 2017-$482.41K-1055.9%
Q2 FY2017Jun 30, 2017-$265.31K–
Q1 FY2017Mar 31, 2017$918.21K–
Q4 FY2016Dec 31, 2016$119.31K–
Q3 FY2016Sep 30, 2016$50.47K–

More ImmuCell figures

See a number that looks wrong?